Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Tamai H, Matsuura T, Komatsu S, Ueda Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group.
Matono T, et al. Among authors: ogawa c.
Hepatol Res. 2025 Sep;55(9):1285-1295. doi: 10.1111/hepr.14224. Epub 2025 Jun 14.
Hepatol Res. 2025.
PMID: 40515751